Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2023 August; 6 (1): 731-736

Novel Drug Delivery Systems for Targeting Tumor Microenvironment

1 Dr.S A Surale-Patil, 2 Dr.V.M.Thorat, 3 Dr.S.A.Jadhav, 4 Dr. A.V.Chavda, 5 Dr.A.S.Shah,

1 Assistant Professor. Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth "Deemed To Be University",Karad –415110, Maharashtra, Emailid-smitaasp73@gmail.com
2 Professor & HOD, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth "Deemed To Be University", Karad –415110, Maharashtra
3 Professor, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth "Deemed To Be University", Karad–415110, Maharashtra
4 Tutor, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed To Be University",Karad –415110, Maharashtra
5 Tutor, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed To Be University", Karad –415110, Maharashtra

Received: 24- June -2023
Revised: 27- July -2023
Accepted: 21- August -2023

Abstract

The advancement of cancer, resistance to treatment, and metastasis are all significantly influenced by the tumor microenvironment (TME). Traditional treatment options face substantial obstacles due to the dynamic and complicated character of this condition. Innovative drug delivery methods have surfaced as viable approaches to accurately target the TME, increasing therapeutic efficacy and reducing off-target effects. This thorough analysis examines cutting-edge medication delivery methods designed to specifically address the complex elements of the TME. It explores methods based on nanoparticles, including liposomes, polymeric nanoparticles, and dendrimers, emphasizing how they can maximize drug accumulation inside the tumor while reducing systemic toxicity. It also covers techniques based on biomaterials, ligand-targeted approaches, stimuli-responsive systems, and cell-mediated drug delivery systems that aim to modulate the TME for better therapeutic effects.

This review also covers new directions and future directions in TME-targeted therapies, such as personalized medicine, nanotechnology developments for precise drug delivery system engineering, the combination of immunomodulation and traditional therapy, exosome-based therapeutics, sophisticated imaging modalities for TME monitoring, artificial intelligence integration in TME analysis, and translational challenges in clinical applications. By permitting precise targeting of the heterogeneous TME and opening the door for more effective and individualized therapeutic interventions, understanding and utilizing these cutting-edge drug delivery methods and developing trends holds great promise to revolutionize cancer therapy paradigms.

Keywords: Tumor Microenvironment, Drug Delivery Systems, Nanoparticles, Stimuli-Responsive, Targeted Therapy

Introduction

Tumor microenvironment (TME): a constantly changing, diverse environment essential to the onset, spread, and response to treatment [1]. The tumor microenvironment (TME) is a complex system that combines both cellular and non-cellular elements to control tumor activity and treatment outcomes. These elements include immune cells, stromal cells, cancer cells, extracellular matrix (ECM), and signaling molecules [2][3]. Its unique characteristics, including its acidic pH, hypoxia, abnormal vasculature, and immunosuppressive environment, provide significant obstacles to conventional cancer treatments [4].

Because of the TME's complex design and physicochemical obstacles, conventional drug delivery devices have a difficult time efficiently targeting it [5]. But new developments in nanotechnology have brought about creative drug delivery methods meant to get over these obstacles. Since they can encapsulate medications and improve their pharmacokinetics and biodistribution while reducing systemic toxicity, nanoparticle-based methods—such as liposomes, polymeric nanoparticles, and dendrimers—have gained popularity [6][7].

Additionally, stimuli-responsive drug delivery devices present a viable approach by utilizing TME environmental cues to initiate regulated drug release, hence improving therapeutic efficacy [8]. These devices allow for site-

specific drug delivery inside the tumor microenvironment and are frequently engineered to respond to changes in pH, enzyme activity, or redox potential [9].

Moreover, the combination of ligand-targeted strategies offers great promise for precisely and selectively delivering medication to particular TME components [10]. Targeted medication administration is made easier while minimizing off-target effects by functionalizing nanoparticles with ligands that identify overexpressed receptors or antigens on cancer cells or stromal components [11].

The investigation of biomaterial-based tactics targeted at modifying the TME's constituent parts has also been prompted by its complex nature [12]. Novel approaches to improving drug delivery and therapeutic responses are provided by biomaterials tailored to change the physical or biological characteristics of the TME, such as immune regulation or extracellular matrix remodeling [13].

Another cutting-edge strategy that targets and delivers therapeutic drugs to the TME is cell-mediated drug delivery systems, which take advantage of the natural characteristics of cells, such as immune cells or designed cellular carriers [14][15]. Using these cells' propensity to gravitate toward tumor locations improves medication accumulation in the TME, increasing therapeutic efficacy and reducing systemic toxicity [16].

The goal of this review is to thoroughly examine these cutting-edge drug delivery systems that are specifically designed to target the complex components of TMEs, outlining how they could transform cancer treatments.

Nanoparticle-Based Drug Delivery Systems

Because of their special physicochemical characteristics, nanoparticles have emerged as attractive delivery systems for therapeutic medicines to the tumor microenvironment (TME) [1]. Among these, liposomes, polymeric nanoparticles, and dendrimers have attracted a lot of interest due to their capacity to encapsulate various medications and increase their TME bioavailability [2].

Lipid-based vesicles called liposomes have the ability to encapsulate pharmaceuticals that are hydrophilic or hydrophobic while still having good biocompatibility [3]. Because of their adaptability, surface modification can improve targeting and enable controlled release inside the TME [4].

Biodegradable polymers are used to create polymeric nanoparticles, which have customizable characteristics that enable enhanced pharmacokinetics and sustained drug release [5]. Through the increased permeability and retention (EPR) effect, these nanoparticles can be designed to elude immune identification, extend circulation, and enhance accumulation within tumors [6].

Highly branched macromolecules called dendrimers show exact control over their size, shape, and surface functions, which allows for targeted delivery and customized drug encapsulation [7]. Their multifunctionality is made possible by their dendritic topology, which facilitates particular interactions with the TME components [8].

Additionally, these systems based on nanoparticles can be designed to get past obstacles found in the tumor microenvironment (TME), like the thick extracellular matrix and cellular efflux mechanisms, which would improve medication uptake and penetration at the tumor site [9-11].

A viable approach to maximizing drug delivery to the TME and enhancing therapeutic efficacy while reducing systemic toxicity is to employ nanoparticle-based drug delivery devices.

Stimuli-Responsive Drug Delivery Systems

Because they may adjust medication release in response to certain stimuli in the tumor microenvironment (TME), stimuli-responsive drug delivery systems have attracted a lot of attention [1]. To accomplish controlled and targeted drug administration, these systems take use of a variety of endogenous or exogenous stimuli, such as temperature fluctuations, enzyme activity, pH variations, and redox potential [2].

The purpose of pH-responsive systems is to take advantage of the acidic TME environment, which is distinguished by a lower pH than normal tissues [3]. Drug release within the tumor is triggered by pH-sensitive moieties or pH-responsive polymers found in nanoparticles, which change their physicochemical properties in acidic

environments [4]. For example, in reaction to the acidic pH of the TME, pH-sensitive liposomes can experience instability or membrane fusion, releasing their payload [5].

Drug release is triggered by overexpressed enzymes in the TME, such as matrix metalloproteinases (MMPs), in enzyme-responsive systems [6]. When particular enzymes come into contact with nanoparticles that are fitted with enzyme-cleavable linkers or substrates, they change structurally, which makes it easier for the medicine to be released at the tumor location [7].

Redox-responsive systems take advantage of the redox imbalance that is disrupted in cancer cells, which is marked by increased glutathione and other reducing agent levels [8]. When intracellular glutathione levels are high, nanocarriers that include redox-sensitive links or disulfide linkages selectively degrade, allowing for the release of drugs into tumor cells [9].

Drug release is triggered by temperature differences between the TME and normal tissues in temperature-responsive systems [10]. Temperature-induced phase transitions or structural alterations in thermosensitive nanoparticles allow for precise medication delivery into tumors [11].

Drug release within the TME is more precise and efficient when many stimuli-responsive mechanisms are integrated into a single nanosystem [12]. Drug delivery kinetics can be precisely controlled by hybrid systems that can react to various inputs either sequentially or concurrently, improving therapeutic outcomes [13].

Moreover, multifunctional nanocarriers containing targeting ligands or imaging agents can be created by combining these stimuli-responsive devices, allowing for simultaneous drug delivery and therapeutic response monitoring [14]. Monitoring drug release kinetics and evaluating treatment effectiveness within the TME are made easier by real-time imaging methods [15].

Stimuli-responsive drug delivery devices have great potential to improve drug accumulation at the tumor site and minimize off-target effects, thus increasing the therapeutic index of anticancer medicines. These devices have the potential to revolutionize cancer treatment tactics due to their precise spatiotemporal control and versatile architecture.

Ligand-Targeted Drug Delivery to TME Components

Tumor microenvironment (TME) components can receive therapeutic drugs precisely and selectively thanks to targeted drug delivery systems that use ligand-mediated techniques [1]. To identify and attach to overexpressed receptors or antigens on cancer cells, stromal cells, or the vasculature within the tumor microenvironment (TME), ligands such as antibodies, peptides, aptamers, or small molecules are carefully conjugated to nanocarriers [2].

In order to facilitate receptor-mediated endocytosis and intracellular drug release, antibody-based targeting techniques involve conjugating monoclonal antibodies specific to tumor-associated antigens (TAAs) on cancer cells [3]. When TAAs like HER2, EGFR, or CD20 are recognized, drugs can be delivered to cancer cells specifically while avoiding healthy tissues [4].

Peptide ligands are advantageous in that they can target several TME components because of their small size and excellent selectivity. When peptides such as RGD (Arg-Gly-Asp) motifs attach to overexpressed integrin receptors on tumor endothelial cells, the accumulation and penetration of nanoparticles within the tumor vasculature are enhanced [5].

Short, single-stranded nucleic acid ligands chosen by systematic ligand evolution by exponential enrichment (SELEX) are used in aptamer-based targeting. Aptamers allow for accurate targeting and effective intracellular drug administration because they are specific to surface proteins or receptors on cancer cells or tumor-associated stromal cells [6].

Receptor-mediated endocytosis is facilitated by small molecule ligands that target transporters or receptors that are overexpressed in the TME, such as transferrin or folate receptors. This enhances drug release and nanoparticle internalization into cancer cells [7].

Furthermore, different ligands can be included into multifunctional nanocarriers thanks to their clever design, which increases targeting specificity and efficacy within the heterogeneous TME [8]. A synergistic effect can be

achieved by combining multiple ligands that target different components of the TME, thereby improving the transport of therapeutic payloads and increasing nanoparticle accumulation [9].

A thorough understanding of the molecular environment and TME heterogeneity is essential for the effectiveness of ligand-targeted drug delivery systems. Constant refinement of ligand selection and conjugation techniques is required due to dynamic changes in TME components, such as receptor density or antigen expression patterns [10].

Moreover, developments in nanotechnology make it possible to create stimuli-responsive or activatable ligands, which improve ligand-receptor interactions and targeted drug release by undergoing structural changes or activation in response to TME-specific cues [11].

Because ligand-targeted drug delivery methods are precise and selective, they may be able to minimize systemic toxicity while effectively addressing the problems caused by TME heterogeneity. The successful clinical application of these tailored techniques depends on ongoing research into TME dynamics, conjugation methodologies, and ligand selection.

Biomaterial-Based Strategies for TME Modulation

In order to enhance medication delivery and therapeutic results, biomaterials provide flexible platforms for engineering techniques targeted at altering the tumor microenvironment (TME) [1]. To modify TME components, such as the extracellular matrix (ECM), immune cell interactions, and angiogenic processes, among others, these tactics entail the creation and deployment of biomaterials [2].

One important strategy is ECM remodeling, in which biomaterials are used to change the chemical and physical characteristics of the ECM inside the TME [3]. By modifying the stiffness and architecture of extracellular matrix (ECM), injectable hydrogels or scaffolds made of biocompatible polymers, like hyaluronic acid or collagen derivatives, enable the controlled release of bioactive molecules or therapeutic substances [4]. By removing ECM-induced barriers, these changes can improve medication penetration and distribution within tumors [5].

The goal of immunomodulatory biomaterials is to rewire the immunosuppressive TME to promote immune responses against tumors [6]. Immunomodulatory drugs, such as cytokines, checkpoint inhibitors, or immunomodulatory nucleic acids, can be included into nanoparticles or scaffolds to enhance immune cell activation and recruitment while inhibiting immunosuppressive signals [7]. These biomaterial-based immunomodulatory techniques have the potential to improve tumor regression and boost immunotherapies' effectiveness [8].

Pro- or anti-angiogenic factors are released into the TME under regulated conditions as part of the biomaterials-based angiogenesis regulation process [9]. Biomaterial-based delivery systems that contain growth factors, angiogenic inhibitors, or small molecules can be used to control neovascularization, which prevents the creation of aberrant vessels and improves the accessibility of drugs to tumors [10]. Furthermore, biomaterials can be designed to resemble normal tissue extracellular matrix (ECM), which attenuates angiogenic signaling and promotes vascular normalization [11].

Additionally, biomaterials act as vehicles for the co-administration of several therapeutic drugs, enabling sequential or synergistic release to address various TME characteristics [12]. Combinatorial delivery of immunomodulators, anti-angiogenic drugs, and chemotherapeutics using biomaterial-based devices provides a complete method to rewire the TME for better therapeutic results [13].

Scalability, biocompatibility, and biodegradability must all be taken into account when using biomaterial-based techniques in clinical settings [14]. Constant improvements in bioengineering, fabrication methods, and biomaterial design allow customized systems to be developed and adjusted to meet the TME's complicated requirements [15].

For the purpose of maximizing the effectiveness and design of these approaches, more investigation into the interplay between biomaterials and the dynamic TME landscape is needed. The TME can be modulated by biomaterials in a way that greatly increases the effectiveness of anticancer medicines and opens up new avenues for more successful cancer treatment paradigms.

Cell-Mediated Drug Delivery Systems in TME

Utilizing the natural or modified characteristics of cells, cell-mediated drug delivery transports medicinal substances to the tumor microenvironment (TME) [1]. Targeted drug delivery to tumor locations is carried out by a variety of cell types, such as immune cells or specially designed carriers [2].

Immune cells can be used as carriers for medication delivery to the tumor microenvironment (TME) since they naturally have a bias towards tumors, especially macrophages, dendritic cells, or lymphocytes [3]. Therapeutic payloads can be loaded into these cells ex vivo or in vivo, and they can be directed to particular tumor locations to release the cargo inside the TME [4].

Red blood cells and mesenchymal stem cells (MSCs) are examples of engineered cell carriers that can be altered ex vivo to carry targeting ligands or receptors for specific homing to the TME [5]. By acting as conduits for the transportation and release of therapeutic substances at tumor sites, these cells maximize the absorption and effectiveness of drugs while reducing their systemic toxicity [6].

Cell-mediated drug delivery systems present a promising way to enhance targeted drug delivery and therapeutic results in cancer treatment by taking advantage of cells' migratory and homing capacities to access and negotiate the complicated TME [7].

Emerging Trends and Future Perspectives in Targeting Tumor Microenvironment

Targeted therapy is evolving as a result of a number of new developments and potential paths in our understanding of the complex dynamics of the tumor microenvironment (TME).

1. Personalized TME Targeting: Personalized medicine techniques are becoming more and more popular. They use genomic and molecular analysis to customize treatments according to unique TME features. Optimizing therapy responses is made possible by precisely targeting faulty pathways within the TME through the incorporation of patient-specific data into treatment regimens [1].
2. Precision engineering and nanotechnology: As nanotechnology develops, more and more accurate and adaptable medication delivery systems can be created. Engineering approaches that have the potential to achieve unmatched precision in targeting the TME include the creation of smart nanoparticles with triggered medication release and real-time monitoring capabilities [2].
3. Immunomodulation and Combination therapy: Using immunomodulatory drugs in conjunction with traditional therapy is proving to be a powerful tactic. Combination therapies leverage the immune system's capacity to identify and eradicate cancer cells in an effort to surmount immunosuppressive therapeutic mutual exclusion obstacles and improve treatment outcomes [3].
4. Exosome-Based Therapeutics: Small extracellular vesicles released by cells called exosomes show promise in medication delivery and TME regulation. Precision medicine is advanced by naturally and effectively targeting specific TME components with engineered exosomes laden with therapeutic cargo [4-8].
5. Microenvironmental Imaging and Monitoring: To evaluate TME characteristics and treatment responses, high-resolution imaging technologies and non-invasive monitoring approaches are essential. Technological developments in imaging modalities, such as molecular imaging and multiparametric MRI, enable real-time tracking of TME changes, supporting therapy optimization [5-9].
6. Artificial Intelligence in TME Analysis: Comprehensive data interpretation is made possible by the integration of machine learning algorithms and artificial intelligence (AI) into TME analysis. Predictive models powered by artificial intelligence (AI) aid in finding new therapeutic targets and forecasting patient reactions, opening the door to more successful TME-targeted treatments [8-10].
7. Clinical Translation: Issues and Difficulties There are still obstacles to overcome in getting TME-targeted treatments from preclinical research to clinical use, despite great advancements. Resolving concerns about repeatability, scalability, and safety is still essential for a successful clinical translation [7].
   In conclusion, the field of TME-targeted therapeutics is developing and offers promising paths toward accurate and efficient cancer treatment. To fully realize the promise of TME-targeted therapies and transform cancer care, more investigation into these new trends is necessary, as is tackling translational issues.

References

1. Dang, Y., & Guan, J. (2020). Nanoparticle-based drug delivery systems for cancer therapy. *Smart materials in medicine, 1*, 10–19. https://doi.org/10.1016/j.smaim.2020.04.001

2. Jia, R., Teng, L., Gao, L., Su, T., Fu, L., Qiu, Z., & Bi, Y. (2021). Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy. *International journal of nanomedicine*, *16*, 1525–1551. https://doi.org/10.2147/IJN.S293427
3. He, Q., Chen, J., Yan, J., Cai, S., Xiong, H., Liu, Y., Peng, D., Mo, M., & Liu, Z. (2020). Tumor microenvironment responsive drug delivery systems. *Asian journal of pharmaceutical sciences*, *15*(4), 416–448. https://doi.org/10.1016/j.ajps.2019.08.003
4. Desai, N., Hasan, U., K, J., Mani, R., Chauhan, M., Basu, S. M., & Giri, J. (2023). Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. *Acta biomaterialia*, *161*, 1–36. https://doi.org/10.1016/j.actbio.2023.03.004
5. Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021). Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. *International journal of nanomedicine*, *16*, 1313–1330. https://doi.org/10.2147/IJN.S289443
6. Tang, L., Mei, Y., Shen, Y., He, S., Xiao, Q., Yin, Y., Xu, Y., Shao, J., Wang, W., & Cai, Z. (2021). Nanoparticle-Mediated Targeted Drug Delivery to Remodel Tumor Microenvironment for Cancer Therapy. *International journal of nanomedicine*, *16*, 5811–5829. https://doi.org/10.2147/IJN.S321416
7. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020). Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. *Frontiers in molecular biosciences*, *7*, 193. https://doi.org/10.3389/fmolb.2020.00193
8. Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013). Role of integrated cancer nanomedicine in overcoming drug resistance. *Advanced drug delivery reviews*, *65*(13-14), 1784–1802. https://doi.org/10.1016/j.addr.2013.07.012
9. Gavas, S., Quazi, S., & Karpiński, T. M. (2021). Nanoparticles for Cancer Therapy: Current Progress and Challenges. *Nanoscale research letters*, *16*(1), 173. https://doi.org/10.1186/s11671-021-03628-6
10. Cerqueira, B. B., Lasham, A., Shelling, A. N., & Al-Kassas, R. (2015). Nanoparticle therapeutics: Technologies and methods for overcoming cancer. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V*, *97*(Pt A), 140–151. https://doi.org/10.1016/j.ejpb.2015.10.007
11. Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017). Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*, *31*, 15–30. https://doi.org/10.1016/j.drup.2017.05.002
12. Mukherjee, B., Das, S., Chakraborty, S., Satapathy, B. S., Das, P. J., Mondal, L., Hossain, C. M., Dey, N. S., & Chaudhury, A. (2014). Potentials of polymeric nanoparticle as drug carrier for cancer therapy: with a special reference to pharmacokinetic parameters. *Current drug metabolism*, *15*(6), 565–580. https://doi.org/10.2174/1389200215666140605150703
13. Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011). Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*, *14*(3), 150–163. https://doi.org/10.1016/j.drup.2011.01.003
14. Pérez-Herrero, E., & Fernández-Medarde, A. (2015). Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V*, *93*, 52–79. https://doi.org/10.1016/j.ejpb.2015.03.018
15. Rahman, M. M., Islam, M. R., Akash, S., Harun-Or-Rashid, M., Ray, T. K., Rahaman, M. S., Islam, M., Anika, F., Hosain, M. K., Aovi, F. I., Hemeg, H. A., Rauf, A., & Wilairatana, P. (2022). Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, *153*, 113305. https://doi.org/10.1016/j.biopha.2022.113305